Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 801–900 of 1,001
A rational approach to the evaluation and management of patients with hyperprolactinemia
Aldahmani, K. M., Almalki, M., & Beshyah, S. (2020) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/ijmbs.ijmbs_38_20 · Cited by 9
Zoli, M., Guaraldi, F., Zoia, C., Corte, E. L., Asioli, S., Bongetta, D., Rustici, A., & Mazzatenta, D. (2020) · Pituitary · doi:10.1007/s11102-020-01107-2 · Cited by 8
Antipsychotic use and fracture risk: An evaluation of incidence at a Veterans Affairs medical center
Weaver, J., Kawsky, J., & Corboy, A. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.01.006 · Cited by 7
“The use of some antipsychotics (eg, risperidone) has been associated with levels exceeding 200 mg/L.(3) The package inserts of many antipsychotics state that ‘‘longstanding hyperprolactinemia when associated with hypogonadism may lead to decreased bone density’’ in patients of both sexes.”
BackgroundInfluentialKe, X., Wang, L., Duan, L., Yang, H., Jia, Y., Qiu, L., Pan, H., Gong, F., & Zhu, H. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117358 · Cited by 6
Sun, S., Jin, W., Hou, T., Tong, S., Zhou, S., Hong, L., Yao, K., Zhao, K., & Zheng, T. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06023-4 · Cited by 6
“Hyperprolactinemia may result in numerous unfavorable clinical outcomes such as irregular menses or amenorrhea, hypogonadism, subfer-tility, osteoporosis, and fracture risk [12, 13].”
BackgroundRudman, Y., & Shimon, I. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.11.001 · Cited by 6
Cela, E., Alcubierre, D. D., & Sbardella, E. (2024) · Clinical Endocrinology · doi:10.1111/cen.15182 · Cited by 11
“Specifically, cabergoline is regarded as the cornerstone of medical treatment for patients with hyperprolactinemia due to its superior therapeutic efficacy, tolerability and patients compliance compared to other DAs [73 – 76].”
Rouf, S., Berrabeh, S., Zarraa, L., & Latrech, H. (2024) · Journal of Medicine and Life · doi:10.25122/jml-2024-0015 · Cited by 6
A Comprehensive Review of Thyroid Dysfunction: Hidden Player in Male Infertility
Babatunde, E. M., & Emokpae, M. A. (2024) · Fertility & Reproduction · doi:10.1142/s2661318224300046 · Cited by 7
Andereggen, L., Christ, E., Stieger, A., Luedi, M. M., & Huber, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-90250-6 · Cited by 6
“Gender-specific differences in prolactinomas are well-documented phenomena 22,35 .”
InfluentialBoyke, A. E., Menaker, S., Nunez, A., Black, K. L., & Ljubimov, V. A. (2025) · Journal of Xenobiotics · doi:10.3390/jox15030071 · Cited by 6
“Given the complex interplay between the hypothalamus and pituitary, disruption via inflammation or cellular proliferation may lead to endocrine abnormalities [16].”
Hyperprolactinemia in children and adolescents: clinical characteristics and etiological spectrum
Kilci, F., Sarıkaya, E., Murat, N. Ö., Deniz, A., Kara, İ., & Sari, Ü. S. (2025) · European Journal of Pediatrics · doi:10.1007/s00431-025-06200-x · Cited by 6
“Although prolactin-secreting tumors are the leading cause of pathological hyperprolactinemia, other tumors affecting the hypothalamic-pituitary region, such as NFPAs, craniopharyngiomas, and dysgerminomas, may also present with hyperprolactinemia due to pituitary stalk compression [4, 6, 21, 22].”
Wu, X., Sun, C., Tian, W., Bao, Z., Gao, H., Wang, J., Lu, X., & Wang, Q. (2025) · BMC Surgery · doi:10.1186/s12893-025-03001-9 · Cited by 6
Li, S., Jiang, Q., Wang, Q., Li, X., Wang, Z., Xu, L., Luo, S., Wang, Y., Zhang, H., Shu, K., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104077 · Cited by 7
“Clinical drug resistance was defined as failure of serum prolactin (PRL) to return to normal or recover gonadal function, plus 30% reduction in tumor diameter or 50% in volume, after 3 – 6 months of continuous tolerable-dose medication [21,22].”
Sharaibi, O. J., & Afolayan, A. J. (2017) · Asian Journal of Biochemistry · doi:10.3923/ajb.2017.91.98 · Cited by 6
Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else
Cho, A., Vila, G., Marik, W., Klotz, S., Wolfsberger, S., & Micko, A. S. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.901385 · Cited by 6
“Historically, sellar lesions causing serum prolactin levels greater than 200 ng/mL were considered to be prolactinomas (6, 11, 12).”
BackgroundKrysiak, R. G., Kowalcze, K. E., & Okopień, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093208 · Cited by 7
Kamrul-Hasan, A. B. M., & Aalpona, F. T. Z. (2023) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2023.100153 · Cited by 8
Alzahrani, A. S., Nafisah, A. B., Alswailem, M. M., Moria, Y., Poprawski, D. M., Al‐Hindi, H., & Pacák, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1273093 · Cited by 6
Andereggen, L., Tortora, A., Schubert, G. A., Musahl, C., Frey, J., Stieger, A., Kobel, B., Luedi, M. M., Roethlisberger, M., Mariani, L., et al. (2024) · Acta Neurochirurgica · doi:10.1007/s00701-024-06213-9 · Cited by 6
“The upper limit of PRL levels was set at 20 µg/L [44].”
BackgroundBreast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia
Dery, L., Shimon, I., Rudman, Y., Masri‐Iraqi, H., Kushnir, S., Shochat, T., Cooper, O. B., & Akirov, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02492-2 · Cited by 6
Resolution of Visual Field Defect in Macroprolactinoma After Treatment With Cabergoline
Shibue, K., Yamakawa, M., Nishida, N., & Hamasaki, A. (2022) · Cureus · doi:10.7759/cureus.25548 · Cited by 6
“Cabergoline use is also associated with a favorable prognosis regarding visual acuity [13,14].”
BackgroundProlactinoma - which patients react favorably to cabergoline medication?
Karataş, S., Hacıoğlu, Y., & Rakicioglu, T. (2022) · Endocrine Regulations · doi:10.2478/enr-2022-0030 · Cited by 6
Chen, X., Yang, L., Li, J., & Tan, H. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01150-z · Cited by 7
Padovan, M., Cerretti, G., Caccese, M., Barbot, M., Bergo, E., Occhi, G., Scaroni, C. M., Lombardi, G., & Ceccato, F. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2185221 · Cited by 6
Jiménez-Canizales, C. E., Rojas, W., Alonso, D., Romero, I., Rodríguez, S. C. T., Veronesi, L. A., Modica, R., & Colao, A. A. L. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02080-w · Cited by 11
Operative treatment of cystic prolactinomas: a retrospective study
Su, W., He, K., Yang, Y., Xu, J., Li, X., Tang, H., Yang, J., & Yang, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01343-0 · Cited by 6
“Binding to the dopamine subtype 2 receptor (D2R) on lactotroph cells, DA can suppress PRL secretion, shrink tumor size and restore gonadal function effectively [10].”
BackgroundInterpreting raised serum prolactin results
Levy, A. (2014) · BMJ · doi:10.1136/bmj.g3207 · Cited by 6
Serum Survivin Increases in Prolactinoma
Dellal, F. D., Niyazoğlu, M., Görar, S., Ademoglu, E. N., Candan, Z., Bekdemir, H., Hacıoğlu, Y., & Kaya, F. Ö. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2098w · Cited by 6
“Treatment is necessary in symptomatic patients and the primary therapeutic choice is medical therapy rather than surgery because the disease can be controlled, even cured with treatment of dopamine agonist in most cases [18, 19].”
BackgroundEctopic posterior pituitary causing hyperprolactinemia
Iacovazzo, D., Lugli, F., & Giampietro, A. (2012) · Endocrine · doi:10.1007/s12020-012-9730-z · Cited by 6
Long-term evolution and outcomes of microprolactinoma with medical treatment
Llanes, M. M. D. S.-O., Melero, V. M. A., & Albarrán, A. J. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.11.006 · Cited by 6
Dellal, F. D., Özdemir, D., Aydın, C., Kaya, G., Ersoy, R., & Çakır, B. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/3576024 · Cited by 6
“In addition, it was reported that 20% of patients with macroprolactinemia have galactorrhea and 45% have oligo/ amenorrhea [5].”
Hyperprolactinaemia: A guide for psychiatrists
Wadoo, O., Shah, A. J., Hall, R., & Mamoojee, Y. H. (2017) · BJPsych Advances · doi:10.1192/apt.bp.115.014977 · Cited by 8
Jean, W. C., & Felbaum, D. R. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.04.029 · Cited by 6
“As prolactin levels rise naturally with pregnancy, monitoring this is not reliable, nor recommended, for detecting tumor progression [3].”
Preoperative Stratification of Transsphenoidal Pituitary Surgery Patients Based on Surgical Urgency
Zaidi, H. A., Wang, A. J., Coté, D. J., Smith, T. R., Prevedello, D. M., Solari, D., Cappabianca, P., Quiroga, M., & Laws, E. R. (2017) · Neurosurgery · doi:10.1093/neuros/nyx073 · Cited by 6
Indications for surgical treatment of prolactin-secreting pituitary adenomas
Kalinin, P. L., Астафьева, Л. И., Кадашев, Б. А., & Ismailov, D. B. (2017) · Burdenko s Journal of Neurosurgery · doi:10.17116/neiro2017815117-124 · Cited by 7
Precision medicine in the medical management of pituitary tumors
Wildemberg, L. E., Kasuki, L., & Gadelha, M. R. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.02.001 · Cited by 6
Novel Mutations in Serbian MEN1 Patients: Genotype-Phenotype Correlation
Isailovic, T. V., Milicevic, I., Μacut, D., Petakov, M. S., Ognjanovic, S. I., Popovic, B. M., Antić, I. B., Bogavac, T., Kovačević, V. E., Ilic, D. S., et al. (2018) · Journal of Medical Biochemistry · doi:10.2478/jomb-2018-0013 · Cited by 7
Start low, go slowly – mental abnormalities in young prolactinoma patients under cabergoline therapy
Brichta, C., Wurm, M., Krebs, A., Schwab, K. O., & van der Werf-Grohmann, N. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0475 · Cited by 7
Pituitary tumours in MEN1 syndrome — the new insight into the diagnosis and treatment
Rogoziński, D., Gilis‐Januszewska, A., Skalniak, A., Kluczyński, Ł., Pantofliński, J., & Hubalewska–Dydejczyk, A. (2019) · Endokrynologia Polska · doi:10.5603/ep.a2019.0026 · Cited by 6
Abe, D., Ogiwara, T., Nakamura, T., Ichinose, S., Fujii, Y., Hanaoka, Y., Ito, K., & Horiuchi, T. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.08.129 · Cited by 6
Patología hipofisaria y gestación
Valassi, E. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.07.007 · Cited by 10
Gamma knife radiosurgery for high-risk lactotroph adenomas: Long-term results
Kara, M., Samancı, Y., Yılmaz, M., Şengöz, M., & Peker, S. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.01.025 · Cited by 6
Asha, H. S., Pai, R. B., Ramamoorthy, H., Sakhti, D., Manipadam, M. T., Kapoor, N., Paul, T. V., Jebasingh, F., Thomas, N., Abraham, D. T., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1402-0183 · Cited by 6
Hyperprolactinemia in Adults with Prader-Willi Syndrome
Sjöström, A., Pellikaan, K., Sjöström, H., Goldstone, A. P., Grugni, G., Crinò, A., de Graaff, L. C. G., & Höybye, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163613 · Cited by 6
Tang, C., Zhu, J., Yuan, F., Yang, J., Cai, X., & Ma, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02541-4 · Cited by 6
Waldman, I. N., & Legro, R. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813209-8.00026-1 · Cited by 11
Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
Davoudi, Z., Hallajnejad, M., Jamali, E., & Honarvar, M. (2022) · Clinical Case Reports · doi:10.1002/ccr3.6087 · Cited by 5
Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma
Varan, E. O., & Gurvit, H. I. (2022) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000320 · Cited by 8
Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments
Chevalier, B., Jannin, A., Espiard, S., Merlen, E., Béron, A., Lion, G., Vantyghem, M., Huglo, D. G., Cortet‐Rudelli, C., & Baillet, C. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104144 · Cited by 7
How often should we perform magnetic resonance imaging (MRI) for the follow-up of pituitary adenoma?
Constantinescu, S. M., Duprez, T. P. J., Bonneville, J., & Maiter, D. M. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.03.004 · Cited by 7
The Dark Side of Dopamine Agonist Therapy in Prolactinoma Management
Ananthakrishnan, S. (2017) · AACE Clinical Case Reports · doi:10.4158/ep161709.co · Cited by 6
Chentli, F., Azzoug, S., Daffeur, K., Akkache, L., Zellagui, H., Haddad, M., & Kalafate, N. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.152771 · Cited by 6
“They usually account for 30–40% of all pituitary tumors[1] although their incidence in autopsy series is greater than 50%.”
BackgroundChemiluminescence systems; do all lead to same results in prolactin analysis?
Farzami, M. R., & Aliasgharpour, M. (2017) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-017-0305-7 · Cited by 6
Nagendra, L., Dutta, D., Mondal, S., Kapoor, N., Joshi, A., & Bhattacharya, S. (2024) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101453 · Cited by 5
Güneş, M., Güneş, E., & Hacıhasanoğlu, A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.10.013 · Cited by 5
Kilci, F., Sarıkaya, E., Murat, N. Ö., & Deniz, A. (2025) · Endocrine · doi:10.1007/s12020-025-04176-0 · Cited by 5
“Dopamine agonists (DA), the fi rst-line treatment for pro-lactinomas, normalize prolactin levels and reduce tumor size by more than 50% in 80 – 90% of patients; cabergoline is generally more effective and better tolerated than bromo-criptine [7, 24, 25].”
The impact of pituitary adenomas on cognitive performance: a systematic review
Young, T.-C., Lin, K.-Y., Li, W.-C., Huang, C.-N., & Tsai, W.-H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1534635 · Cited by 7
Ertörer, M. E., Tuncer, F. N., Doğanşen, S. Ç., Tanrıkulu, S., Selçukbiricik, Ö. S., Topaloğlu, Ö., Evran, M., Kadıoğlu, P., Aydin, S., Canbaz, B., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-08610-1 · Cited by 5
“In PRL-secreting adenomas, serum PRL levels are usually above 250 ng/ml and the presence of galactorrhea and sexual dysfunction makes the diagnosis of prolactinoma (15).”
Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta‐Analysis
Chakraborty, A. M., & Rastogi, A. (2025) · Clinical Endocrinology · doi:10.1111/cen.15304 · Cited by 5
Clinically Nonfunctioning Pituitary Adenomas
Habib, U., & Tritos, N. A. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.06.002 · Cited by 6
Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets
Hjelholt, A. J., Tei, R., Diener, H. C., & Jørgensen, J. O. L. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70098 · Cited by 11
“62,63 Clinical reports indicate that dopamine receptor agonists have beneficial effects in patients with prolactin-associated headache, including migraine.”
Zheng, A., Tang, D., He, H., & Liang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1618412 · Cited by 5
Yogeeta, F., Rauf, S. A., Devi, M., Imran, K., Ahmed, R., Aruwani, P. K., Saad, M., Tooba, F., Hashmani, F. Z., Ibrahim, M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002308 · Cited by 9
“Pharmacological therapy is effective in most prolactinomas, and the mainstay of care typically consists of dopamine agonists (DA) [6] , Cabergoline being the most commonly used drug to regulate prolactin levels and reduce tumour mass [9] .”
BackgroundWang, M., Yu, Y., Han, Y., Yang, Y., Jiang, W., Liu, J., Yan, L., & Cui, G. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29531 · Cited by 5
Fan, Y., Guo, S., Tao, C., Fang, H., Mou, A., Feng, M., & Wu, Z. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.09.023 · Cited by 5
Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas
Andereggen, L., & Christ, E. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-04958-6 · Cited by 5
“The upper limit for PRL levels was set at 20 µg/L [26].”
Bostan, H., Uçan, B., Düğer, H., Hepşen, S., Kayıhan, S., Dilli, A., Ünsal, İ. Ö., Çakal, E., & Kızılgül, M. (2025) · Pituitary · doi:10.1007/s11102-025-01512-5 · Cited by 5
Lee, Y. J., Hong, J. W., Kim, Y., Kim, J., Kang, C. W., Lee, M.-H., Moon, J. H., Kim, E. H., Ku, C. R., & Lee, E. J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf025 · Cited by 5
Анатольевна, Б. О. (2015) · Problems of Balneology Physiotherapy and Exercise Therapy · doi:10.17116/kurort2015322-26 · Cited by 5
Pièges diagnostiques des hyperprolactinémies chez la femme
Paepegaey, A. C., Veron, L., Wimmer, M.-C., & Christin‐Maître, S. (2016) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2016.02.008 · Cited by 10
Astaf’eva, L., Shishkina, L., Kalinin, P. L., Кадашев, Б. А., Mel'nichenko, G. A., Tserkovnay, D., & Sharipov, O. I. (2020) · Asian Journal of Neurosurgery · doi:10.4103/ajns.ajns_16_20 · Cited by 5
“388 Asian Journal of Neurosurgery | Volume 15 | Issue 2 | April-June 2020 From the moment of the active introduction (beginning of the 2000s) of cabergoline, which has proven to be an effective and safe drug.[1,2] It has become the priority treatment for PRL secreting tumors.”
BackgroundInfluentialThe prevalence of silent acromegaly in prolactinomas is very low
Bona, C., Prencipe, N., Jaffrain‐Rea, M., Carosi, G., Lanzi, R., Ambrosio, M. R., Pasquali, D., Vettor, R., Cannavò, S., Ghigo, E., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01338-x · Cited by 5
Pituitary tumor apoplexy associated with extrapontine myelinolysis during pregnancy: A case report
Ye, W., Huang, W., Chen, L., Yao, C., Sheng, S., Liu, Z., Xue, C., & Xing, W. (2021) · Medicine · doi:10.1097/md.0000000000025075 · Cited by 5
“However, surgery seems appropriate for patients who fail to respond to conservative treatment or cannot tolerate dopamine agonists.([16]) Neurosurgical intervention should be considered in cases with persistent visual field defects or”
Kim, H., Hong, J.-W., Moon, J.-H., Ahn, S. S., Kim, E. H., Lee, S., Lee, E. J., Park, Y. W., & Ku, C. R. (2021) · Cancers · doi:10.3390/cancers13215374 · Cited by 7
“The treatment goals for giant prolactinomas include normalization of PRL with recovery of altered pituitary axes, but, more importantly, reduction of tumor size with relief of compression of adjacent structures, particularly the optic chiasm and cranial nerves [4].”
BackgroundPBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
Zhu, K., Cheng, X., Wang, S., Zhang, H., Zhang, Y., Wang, X., Chen, Y., & Wu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.706909 · Cited by 5
“Prolactinoma is treated mainly by surgery and drug therapy to improve tumor occupying and hormone disturbance (10).”
BackgroundCoronel, D. A. S., de la Peña, F. R., Palacios‐Cruz, L., Cuevas, D., & Duran, S. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2050259 · Cited by 5
“Hyperprolactinaemia (HyperPRL) is a common endocrinological disorder with a prevalence reported of 4% in the general population and up to 70% and 90% in the psychiatric population (Melmed et al., 2011; Pigato et al., 2015).”
BackgroundYagnik, K. J., Erickson, D. Z., Bancos, I., Choby, G. W., Laack, N. N. I., & Gompel, J. J. V. (2022) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/a-1934-9028 · Cited by 10
Pituitary adenomas registry in Thailand
Kwancharoen, R., Deerochanawong, C., Peerapatdit, T., & Salvatori, R. (2023) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2023.07.026 · Cited by 11
“Cabergoline has been reported to have higher effectiveness than bromocriptine [22,24].”
BackgroundCano, A. M. G., Rosillo, M., Lozano, A. G., Mendiguchía, L. J., Pinedo, M. M., Torres, A. R., & Castro, M. A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02803-z · Cited by 7
“In these cases, the degree of prolactin elevation varies according to the pharmacological group (Melmed et al., 2011; Ruljancic et al., 2021; Yuen et al., 2021; Montejo et al., 2016).”
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
Basile, M., Valentini, I., Attanasio, R., Cozzi, R. C., Persichetti, A., Samperi, I., Scoppola, A., Auriemma, R. S., Menis, E. D., Esposito, F., et al. (2024) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2024.2601 · Cited by 5
“As suggested by the international guidelines from the Endocrine Society in 2011 (9) and the GL in 2022 (10), dopamine agonist (DA) is the standard first-line treatment approach for prolactinomas: it normalizes serum PRL levels in nearly 90% of patients with microP and in 75%-80% of patients with MP…”
BackgroundMethodHattori, Y., Tahara, S., Ozawa, H., Morita, A., & Ishii, H. (2024) · Neuroendocrinology · doi:10.1159/000539017 · Cited by 7
Duru, M., Demir, A. N., Öz, A., Kargın, O. A., Altunç, A. T., Demirel, Ö., Arslan, S., Kızılkılıç, O., Poyraz, B. Ç., & Kadıoğlu, P. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02442-y · Cited by 5
Krogh, J. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09916-7 · Cited by 7
B2R-D2R Interaction in Prolactinomas and Nonfunctional Adenomas: Impact on Dopamine Resistance
Abeledo-Machado, A., Argerich, J., Yaneff, A., Vidal, N., García-Roca, C., Bornancini, D., Peña‐Zanoni, M., Gironacci, M. M., Shayo, C., Ciruela, F., et al. (2024) · Endocrinology · doi:10.1210/endocr/bqae144 · Cited by 5
Introini, L., Silva, J., Risso, M., Mendoza, B., & Pineyro, M. M. (2025) · Case Reports in Endocrinology · doi:10.1155/crie/2490132 · Cited by 5
“They have a higher incidence in women aged between 25 and 35, with the majority being microprolactinomas (less than 10 mm) [1, 2].”
InfluentialIncreased Prolactin Concentrations in a Patient with Bipolar Disorder
Schmidt, M., Sofronescu, A. G., Short, B., Nahas, Z. H., & Zhu, Y. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2011.176925 · Cited by 5
Emotionally induced galactorrhoea in a non-lactating female –“Pseudo- Lactation”?
Dissanayake, H. A., Keerthisena, S., Dematapitiya, C., & Katulanda, P. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-98 · Cited by 7
“Minor concerns [1] Line 53, on this case’s grounds it cannot be concluded that “.”
BackgroundInfluentialde Freitas, B. B., Rothen, R. E., Zeni, D., Leães, C. G. S., Oliveira, M. C., Busnello, F. M., & Pereira‐Lima, J. F. S. (2015) · PubMed · doi:10.3305/nh.2015.32.5.9673 · Cited by 5
(2017) · International Journal of Medicinal Plants and Natural Products · doi:10.20431/2454-7999.0302002 · Cited by 6
“Certain medications such as reserpine, antipsychotic drugs, risperidone, phenothiazines, metoclopramide, oral contraceptive pills etc. have been indicted to be responsible for some gynaeacological disorders (Melmed et al., 2011).”
BackgroundLenet, S., & Polychronakos, C. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-229032 · Cited by 5
The problem of female sexuality
Andreeva, E. N., & Sheremetyeva, E. V. (2019) · Russian Journal of Human Reproduction · doi:10.17116/repro20192503140 · Cited by 5
Pituitary Adenomas with Changing Phenotype: A Systematic Review
Guerrero‐Pérez, F., Marengo, A. P., Vidal, N., & Villabona, C. M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1120-8277 · Cited by 5
Christian, Z. K., Hatanpaa, K. J., Auchus, R. J., Hammes, S. R., Patel, A., & Mickey, B. (2020) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2020.100777 · Cited by 5
Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia
Du, X., Ye, F., Li, J., Zhao, Y., Xiao, W., Tang, X., & Zhang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-70668-w · Cited by 5
Biagetti, B., Ferrer, R., Alfayate, R., García, E. Á., Berlanga, E., Casals, G., Salán, M. E., Granada, M. L., Ramos, J. G., Lazareno, N. L., et al. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.12.002 · Cited by 5
Treatment of hyperprolactinemia: A single-institute experience
Chen, T., Lee, C.-H., Yang, M., Shen, C., Yang, Y.-P., Chien, Y., Huang, Y.-F., Lai, C.-M., & Cheng, W.-Y. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000584 · Cited by 4
Guo, R., Wu, Y., Guo, G., Zhou, H., Liu, S., Yao, Z., & Xiao, Y. (2021) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001237 · Cited by 7
“Although some studies used transsphenoidal surgery for prolactin-secreting microadenomas,(21) dopamine agonists are still the first-line treatment for these lesions.(22,23) Before initiating medical treatment, clear detection of the pituitary lesion on MRI could benefit patients with hyperprolactinemia in several ways…”
BackgroundHormonal Laboratory Examination
Pagotto, U., Fanelli, F., & Granata, A. R. M. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_16 · Cited by 5
Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas
Hacışahinoğulları, H., Canturk, S., Doğanşen, S. Ç., & Yarman, S. (2022) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2022.01.002 · Cited by 6
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.